Psoriasis
Conditions
Brief summary
PH-10 is an aqueous hydrogel formulation of rose bengal disodium (RB) for topical administration to the skin, and is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. This phase 2 efficacy and safety study will assess topical PH-10 applied once daily to areas of mild to moderate plaque psoriasis.
Interventions
DRUGPH-10 (0.001% Rose Bengal)
PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
Sponsors
Provectus Pharmaceuticals
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Men or women, age 18 or older. * Presence of mild to moderate plaque psoriasis on the trunk or extremities (excluding palms, soles, scalp, and facial or intertriginous areas). * Fitzpatrick skin type I-VI. * Written informed consent by the subject or legal guardian.
Exclusion criteria
* Women of childbearing potential who are pregnant, attempting to conceive, not using effective contraception, or who are nursing an infant. * Subjects who have received PUVA or systemic antipsoriatic therapy (immunosuppressants, cytostatics, corticosteroids) within 28 days of study initiation (two weeks for methotrexate). * Subjects who have received UVB light therapy within 14 days of study initiation. * Subjects who have received topical antipsoriatic therapy (including corticosteroids, tar, anthralin or Vitamin D analogs) to the study plaque areas within 14 days of study initiation. * Subjects who have received agents posing a clinically significant risk of photosensitivity reaction within 5 half-lives of study initiation. * Subjects who have received any approved or investigational biologic drug therapy for psoriasis within 90 days or 5 half-lives of study initiation. * Subjects who have participated in a clinical research study within 28 days of study initiation. * Subjects with a history of porphyria, systemic lupus erythematosus or xeroderma pigmentosum. * Subjects with clinical conditions that, in the opinion of the Investigator may pose a health risk to the subject by being involved in the study or detrimentally affect regular follow-up of the subject.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy endpoint is Treatment Success, a static endpoint assessed at Day 29 after initial PH-10 treatment and defined as 0 or 1 on all Psoriasis Severity Index (PSI) components and 0 or 1 on the Plaque Response scale. | 28 days |
| The primary safety endpoint is incidence of adverse experiences, including pain and dermatologic/skin toxicity (incidence, severity, frequency, duration and causality). | 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Psoriasis Severity Index (PSI) score changes at each visit from Day 1 pre-treatment. | 8 weeks |
| Plaque Response score changes at each visit from Day 1 pre-treatment. | 8 weeks |
| Pruritus Self-Assessment score changes at each visit from Day 1 pre-treatment. | 8 weeks |
Countries
United States
Outcome results
None listed